PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Stroli – the shopping trolley reimagined for modern needs. The shopping trolley, often associated with a particular image, is an untapped category ready for innovation. The market is flooded with generic, budget-friendly options that lack charm, with the exception of Rolser, which is pricier and claims the green niche. Stroli steps in as the go-to brand, offering a unique approach, positioning, voice, and eco-friendly credentials. Say goodbye to sore hands and plastic bags – Stroli makes shopping a pleasure with its high-quality, stylish trolley bags designed to enhance your convenience and style
days to go:
Extended
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
PLAYin CHOC is an innovative, premium and award-winning manufacturer of vegan organic eco-friendly toys and chocolates. Its products are allergen-free, plastic-free, 100% organic and inspire creative play. Since its launch, PLAYin CHOC has sold approximately 50,000+ units in 21 countries. Additionally, potential stockists for its products are estimated at 100,000 in the UK and 1 million globally. Now, PLAYin CHOC is planning to take its product to the market via high-end food supermarkets; independent food, confectionary and gift shops; travel retail market; direct to the consumer via subscription; and international distributors. Funds raised will be used to increase growth by securing larger and permanent premises and intensify targeted marketing at trade & consumer shows and online.
days to go:
Expired
investment:
£278,450
Gendius is a company that aims to bring pharmaceuticals and health economics, through clinical research and evidence, to the mobile health market. Their latest innovation, Intellin, is an intelligent remote management diabetes platform, with over 140,000 downloads so far. The COVID-19 crisis has highlighted the need for remote home monitoring of patients, and the company feels that its product is a suitable contender in this domain. Intellin has a reliable connection to over 150 medical devices and apps, and also consists of a two-way communication setup with a healthcare professional via a secure dashboard. Gendius is registered as an approved vendor with AstraZeneca in Saudi Arabia and looks to establish deeper relations with the National Health Service (UK) to create a demand for its product. The company will use the investment to scale its business globally, drive commercialisation, offer an opportunity to its stakeholders, and target venture capital.
days to go:
Expired
investment:
£386,829
Rightangled is a healthcare technology company backed by NHS England & regulated by the Care Quality Commission (CQC). It began its journey as a platform that would enable the use of genetic information within the medical practice, in an accurate, streamlined, and affordable way. It gradually established itself as a healthcare provider for screening and diagnostic services. Its Heart DNA Test project, launched in 2017, is helping patients minimize their cardiac risks and enabling doctors to have a complete risk profile for their patients. The project was appreciated and received funding from NHS England. Its next project, Fitness DNA Test, tapped into the fitness and wellbeing markets. Recently, in the wake of the COVID-19 threat, the company has developed a home-based throat swab test to detect the viral infection, by testing viral load presented in its nucleic acid material within (RNA). For its efforts, Rightangled has been featured on CNN, Sky News, LBC radio, Sky News radio, and Newsweek. With the investment, the company aims to release a mobile application by the end of 2020, and develop an AI system to give instant tailored health, diet, and fitness advice to its users based on the data gathered from patient-doctor interactions and patient responses.
days to go:
Expired
investment:
£522,689
Doisy & Dam (D&D) is a confectionery challenger brand that produces a range of dark chocolate products. It claims that its products are sold across the UK and stocked by Amazon, Sainsbury's, Holland & Barrett, Ocado, Boots, and other global markets. D&D's products are created using ethically sourced cocoa, natural ingredients and contain no traces of palm oil. The company aspires to become a contender in the UK confectionery market that was worth £3.9 billion in April 2021. It further points out that people are aware of the health and the sustainability credentials of the products they buy. It intends to target this sentiment and become an established brand. The company states it has grown its sales to over £1 million and aspires to become the best dark chocolate confectioner in the UK. D&D state they will use the investment for marketing, expanding its product range, and growing its export business.
days to go:
Expired
investment:
£515,735
Super U is a health food brand, creating great-tasting and nutritious superfood blends and providing a natural, innovative & convenient way of consuming superfoods, without costing the Earth. The company has 3500+ online consumers and, the social audience has risen to over 8,500 followers. Additionally, Super U has been a finalist for Start-Up Business of the Year and Health & Beauty Business of the Year 2019 - for the Great British Entrepreneur Awards. The funds will be used for growth, marketing and export strategies.
days to go:
Expired
investment:
£160,110
OvuSense is a women's health monitoring platform offering continuous insights into the reproductive cycle. With over 45,000 users and 10 patents, they aim to expand through partnerships, starting with a large IVF clinic chain. Addressing underdiagnosed health issues, their platform provides accurate cycle monitoring, health screening, and treatment tracking. Backed by institutional investors, OvuSense stands out for its predictive capabilities and accuracy in ovulation tracking, empowering women's fertility control.
days to go:
Expired
investment:
£169,920
